Trials / Completed
CompletedNCT04479852
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 319 (actual)
- Sponsor
- Sirtsei Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP-624 | Oral capsule |
| DRUG | Placebo | Oral capsule |
Timeline
- Start date
- 2020-09-30
- Primary completion
- 2022-06-27
- Completion
- 2022-08-09
- First posted
- 2020-07-21
- Last updated
- 2025-06-12
- Results posted
- 2025-06-12
Locations
39 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04479852. Inclusion in this directory is not an endorsement.